rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Bruno Lucidi

Director

Company insider

Files Form 4 as: Director, Atea Pharmaceuticals.

In numbers

Trades disclosed
21
Buys
0
Sells
0
Bought
$0
Sold
$0
Companies
1
Companies where not an officer
1
First trade
29 Oct 2020
Last trade
18 Jun 2026
Last filed
23 Jun 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
AVIR Atea PharmaceuticalsDirector · Biotechnology · last 18 Jun 20260 buys · 0 sells

Activity over time

Not enough dated trades to draw.

Every trade

TradedCompanyWhatAmount
18 Jun 2026filed 23 Jun 2026AVIR Atea PharmaceuticalsBiotechnologySEC FORM 4 Code M—29,600 at $0.00filing
18 Jun 2026filed 23 Jun 2026AVIR Atea Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code M—29,600 at $0.00filing
18 Jun 2026filed 23 Jun 2026AVIR Atea Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—26,700 at $0.00filing
18 Jun 2026filed 23 Jun 2026AVIR Atea Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code M—29,600 at $0.00filing
18 Jun 2026filed 23 Jun 2026AVIR Atea Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—26,700 at $0.00filing
18 Jun 2026filed 23 Jun 2026AVIR Atea Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—37,700 at $0.00filing
18 Jun 2026filed 23 Jun 2026AVIR Atea Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—37,700 at $0.00filing
18 Jun 2026filed 23 Jun 2026AVIR Atea PharmaceuticalsBiotechnologySEC FORM 4 Code M—29,600 at $0.00filing
20 Jun 2025filed 24 Jun 2025AVIR Atea Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—29,600 at $0.00filing
20 Jun 2025filed 24 Jun 2025AVIR Atea Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—41,200 at $0.00filing
20 Jun 2025filed 24 Jun 2025AVIR Atea Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code M—29,600 at $0.00filing
20 Jun 2025filed 24 Jun 2025AVIR Atea PharmaceuticalsBiotechnologySEC FORM 4 Code M—29,600 at $0.00filing
21 Jun 2024filed 21 Jun 2024AVIR Atea Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—29,600 at $0.00filing
21 Jun 2024filed 21 Jun 2024AVIR Atea Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—41,200 at $0.00filing
16 Jun 2024filed 18 Jun 2024AVIR Atea Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code M—33,150 at $0.00filing
16 Jun 2024filed 18 Jun 2024AVIR Atea PharmaceuticalsBiotechnologySEC FORM 4 Code M—33,150 at $0.00filing
16 Jun 2023filed 21 Jun 2023AVIR Atea Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—33,150 at $0.00filing
16 Jun 2023filed 21 Jun 2023AVIR Atea Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—46,750 at $0.00filing
17 Jun 2022filed 21 Jun 2022AVIR Atea Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—61,264 at $0.00filing
18 Jun 2021filed 21 Jun 2021AVIR Atea Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—34,025 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

No trade we could place in a sector.

Related people

Franklin M. BergerDirector · Director at Atea Pharmaceuticals, filing Form 4 there in the last year
Arthur S. KirschDirector · Director at Atea Pharmaceuticals, filing Form 4 there in the last year
Barbara Gayle DuncanDirector · Director at Atea Pharmaceuticals, filing Form 4 there in the last year
Bruce PolskyDirector · Director at Atea Pharmaceuticals, filing Form 4 there in the last year
Polly A. MurphyDirector · Director at Atea Pharmaceuticals, filing Form 4 there in the last year